Study Shows Improvement with Benlysta Plus Standard Lupus Treatment

A new study found that belimumab combined with conventional treatment improved biomarkers and clinical disease activity in patients with systemic lupus erythematosus.  Study investigators wrote, “Taken together, these results suggest that belimumab treatment does not compromise the immune response to infection." Abstract